Ambrx Biopharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMAM research report →
Price Chart
About the company
Ambrx Biopharma Inc. operates as a clinical-stage biotechnology company focused on the discovery and development of precisely engineered biologic medicines. The firm utilizes its unique expanded genetic code technology platform to create these advanced therapies.
- CEO
- Daniel J. O'Connor
- IPO
- 2023
- Employees
- 87
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on AMAM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.77B
- P/E
- -13.86
- PEG
- -0.19
- P/S
- 239.41
- P/B
- 9.17
- EV/EBITDA
- -27.58
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -771.16%
- Net Margin
- -1053.72%
- ROE
- -50.68%
- ROIC
- -43.23%
Latest fiscal year · YoY change
- Revenue
- $7.40M-0.7%
- Gross Profit
- $7.40M-0.7%
- Op Income
- $-57,081,000
- Net Income
- $-77,996,000-14.2%
- EPS
- $-2.02+39.5%
- OCF Growth
- -53.8%
- FCF Growth
- -45.7%
- 52W High
- $28.15
- 52W Low
- $6.55
- 50D MA
- $25.33
- 200D MA
- $16.45
- Beta
- -2.36
- RSI (14)
- 82
- Avg Volume
- 1.94M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ambrx ended 2021 with $170.1 million in cash, expanded its ADC pipeline, and said it expects multiple clinical readouts and trial initiations across 2022.· April 27, 2022
- 2021 IPO raised $142.1 million gross and the company ended the year with $170.1 million in cash and cash equivalents.
- Revenue fell to $7.5 million for full-year 2021 from $13.7 million in 2020; second-half revenue was $2.4 million vs. $7.2 million a year ago.
- Operating expenses increased to $71.9 million for full-year 2021 from $26.8 million in 2020, driven mainly by clinical trial spend and IPO/public-company costs.
- ARX788 remained the lead asset, with positive interim and Phase 1/2 updates in gastric and breast cancer and more data expected in 2022.
- The company also advanced ARX517, ARX305, and ARX102, with several data readouts and trial starts planned for the second half of 2022.
Revenue for the second half of 2021 was $2.4 million, down from $7.2 million in the same period of 2020. Full-year 2021 revenue was $7.5 million, down from $13.7 million in 2020. Operating expenses were $41.5 million in the second half and $71.9 million for full-year 2021, versus $14.3 million and $26.8 million in the prior-year periods. Cash and cash equivalents were $170.1 million at December 31, 2021, and management said that cash should fund planned operations for at least the next 12 months. Looking ahead, management expects second-half 2022 data readouts for ARX788 in ACE-Breast-02 and ACE-Pan Tumor-01, interim Phase 1 data for ARX517, initiation of a Phase 1 trial for ARX305, and an R&D submission for ARX102. They also said ACE-Gastric-02 interim data is now expected in 2023, and the ARX788 adjuvant/I-SPY 2.2 collaboration could provide additional visibility later.
Feng Tian framed 2021 as a year of major progress as a newly public company, highlighting team expansion, board additions, and advancement of the clinical pipeline despite COVID-19 and China lockdown disruptions. He was constructive on ARX788, citing positive data in breast and gastric cancer and saying the asset is supported by multiple upcoming readouts. He also emphasized the breadth of the internal pipeline, with ARX517, ARX305, and ARX102 moving toward key milestones in 2022.
Sonja Nelson said the company generated $2.4 million of revenue in the second half and $7.5 million for full-year 2021, while operating expenses rose to $41.5 million and $71.9 million, respectively. She attributed the higher cost base mainly to increased clinical trial spending, especially for ARX788, plus professional services and fees tied to the IPO and running as a public company. She also reiterated the balance-sheet position: $170.1 million in cash and cash equivalents at year-end, which management believes is sufficient for at least the next 12 months.
Analysts focused on timing, depth, and geography of the pipeline readouts, especially Pan Tumor-01, ARX517, and Breast-02. Management said Pan Tumor-01 includes multiple cohorts and doses, with data later in 2022 guiding future trial design, and that ARX517 is progressing through dose escalation with cohort expansion expected in the second half. On China lockdowns, Tian said ex-China trials should not be impacted materially and that Breast-02 enrollment is already largely complete, though he acknowledged the situation could affect follow-up and data collection to some degree.
The call presented a company with a well-capitalized balance sheet and a broad set of upcoming clinical catalysts. Management sounded confident in ARX788, pointing to positive early efficacy and tolerability signals, better-than-expected ex-China enrollment, and potential differentiation in safety and response rates.
Revenue remains modest and fell year over year, while operating expenses rose sharply as the company pushed its pipeline forward and absorbed IPO-related public-company costs. Management also flagged uncertainty around China lockdowns and said some timelines, particularly follow-up and data collection, could be affected even if ex-China studies are less exposed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 34.6%
- Shares Outstanding
- 63.29M
- Float Shares
- 21.92M
of shares held by institutions
60 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Innovis Asset Management LLC | 31.14K | ▲ 14.31K |
| Bergankdv Wealth Management, LLC | 100 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 11, 23 | O'Connor Daniel J. | other | 750,000 |
| Oct 27, 23 | O'Connor Daniel J. | sell | 50,012 |
| Oct 23, 23 | Cormorant Asset Management, LP | buy | 1,307,311 |
| Sep 18, 23 | Cormorant Asset Management, LP | buy | 751,233 |
| Sep 15, 23 | Cormorant Asset Management, LP | buy | 1,401,505 |
| Sep 1, 23 | DALESANDRO MARGARET | other | 125,000 |
| Sep 1, 23 | DALESANDRO MARGARET | other | 70,833 |
| Sep 1, 23 | DALESANDRO MARGARET | other | 0 |
| Jul 5, 23 | O'Connor Daniel J. | other | 1,216,500 |
| Jul 5, 23 | Nelson Sonja | other | 389,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMAM coverage
Recent articles, reports, and earnings notes.
No research on AMAM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMAM report →Ambrx Shareholders Approve Acquisition by Johnson & Johnson
globenewswire.com · Mar 6
3 Stocks to Buy That Are Up 200% or More in 2024
investorplace.com · Feb 23
Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?
zacks.com · Feb 20
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
businesswire.com · Feb 10
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
businesswire.com · Jan 10
Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J
zacks.com · Jan 9
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
investorplace.com · Jan 8
J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion
cnbc.com · Jan 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.